EMA/678121/2010

European Medicines Agency decision

P/239/2010

of 05 November 2010

on the acceptance of a modification of an agreed paediatric investigation plan for infliximab (Remicade), (EMEA-000549-PIP01-09-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/239/2010

of 05 November 2010

on the acceptance of a modification of an agreed paediatric investigation plan for infliximab (Remicade), (EMEA-000549-PIP01-09-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/62/2010 issued on 19 April 2010,

Having regard to the application submitted by Centocor B.V. on 02 August 2010 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 08 October 2010, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for infliximab (Remicade), powder for concentrate for solution for infusion, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Centocor B.V., Einsteinweg 101, 2333 AG Leiden, The Netherlands.

Done at London, 05 November 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

EMA/612325/2010

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000549-PIP01-09-M01

Scope of the application

Active substance(s):

Infliximab

Invented name:

Remicade

Condition(s):

Rheumatoid arthritis

Juvenile idiopathic arthritis

Psoriatic arthritis

Ankylosing spondylitis

Psoriasis

Crohn's disease

Ulcerative colitis

Authorised indication(s): see Annex II

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Centocor B.V.

Information about the authorised medicinal product: see Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Centocor B.V. submitted to the European Medicines Agency on 02 August 2010 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/62/2010 issued on 19 April 2010.
The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 12 August 2010.

Scope of the modification

Some measures of the original Opinion have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 08 October 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Condition(s)

Rheumatoid arthritis

Juvenile idiopathic arthritis

Psoriatic arthritis

Ankylosing spondylitis

Psoriasis

Crohn's disease

Ulcerative colitis

Authorised indications: see Annex II

2. Waiver

2.1. Condition

Rheumatoid arthritis

Indication:
Reduction of signs and symptoms as well as the improvement in physical function in:
- patients with active disease when the response to disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate, has been inadequate and in patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age.
- for powder for concentrate for solution for infusion, intravenous use
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2.2. Condition

Juvenile idiopathic arthritis

Indication:

Treatment of Juvenile idiopathic arthritis

The waiver applies to:

- Children from birth to less than 24 months
- for powder for concentrate for solution for infusion, intravenous use
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

The waiver applies to:

- Children from 2 to less than 18 years
- for powder for concentrate for solution for infusion, intravenous use
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.3. Condition

Psoriatic arthritis

Indication:

Treatment of active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.

The waiver applies to:

- Children from birth to less than 24 months
- for powder for concentrate for solution for infusion, intravenous use
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

The waiver applies to:

- Children from 2 to less than 18 years
- for powder for concentrate for solution for infusion, intravenous use
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.4. Condition

Ankylosing spondylitis

Indication:

Treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.

The waiver applies to:

- Children from birth to less than 24 months
- for powder for concentrate for solution for infusion, intravenous use
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

The waiver applies to:

- Children from 2 to less than 18 years
- for powder for concentrate for solution for infusion, intravenous use
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.5. Condition

Psoriasis

Indication:

Treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.

The waiver applies to:

- Children from birth to less than 7 years
- for powder for concentrate for solution for infusion, intravenous use
- on the grounds that the disease or condition for which the specific medicinal

  product is intended does not occur in the specified paediatric subset(s).

The waiver applies to:

- Children from 7 to less than 18 years
- for powder for concentrate for solution for infusion, intravenous use
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.6. Condition

Crohn's disease

Indication:

Treatment of severe, active Crohn's disease, in paediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies.

The waiver applies to:

- Children from birth to less than 6 years
- for powder for concentrate for solution for infusion, intravenous use
- on the grounds that the specific medicinal product is likely to be unsafe.

The waiver applies to:

- Children from 6 to less than 18 years
- for powder for concentrate for solution for infusion, intravenous use
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as the needs are already covered.

Indication:

Treatment of moderate Crohn's disease

The waiver applies to:

- Children from birth to less than 18 years
- for powder for concentrate for solution for infusion, intravenous use
- on the grounds that the specific medicinal product is likely to be unsafe.

2.7. Condition

Ulcerative colitis

Indication:

Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.

The waiver applies to:

- Children from birth to less than 2 years
- for powder for concentrate for solution for infusion, intravenous use
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

3. Paediatric Investigation Plan

3.1. Condition to be investigated

Ulcerative colitis

3.1.1. Indication targeted by the PIP

Treatment of moderately to severely active ulcerative colitis.

3.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age.

3.1.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion, intravenous use.

3.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	2	Study 1.

Area	Number of studies	Description
		A randomised, open-label, dose-comparison parallel-group, multicentre trial of infliximab in paediatric patients from 6 to less than 18 years old with moderately to severely active ulcerative colitis. Study 2. Modelling and simulation analysis for pharmacokinetics of infliximab in paediatric patients with ulcerative colitis from 2 to less than 6 years old.

4. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues and efficacy in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2011
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

EU Number	(Invented) name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Content (concentration)	Package size
EU/1/99/116/001	Remicade	100 mg	Powder for concentrate for solution for infusion	Intravenous use	vial (glass)		1 vial
EU/1/99/116/002	Remicade	100 mg	Powder for concentrate for solution for infusion	Intravenous use	vial (glass)		2 vials
EU/1/99/116/003	Remicade	100 mg	Powder for concentrate for solution for infusion	Intravenous use	vial (glass)		3 vials
EU/1/99/116/004	Remicade	100 mg	Powder for concentrate for solution for infusion	Intravenous use	vial (glass)		4 vials
EU/1/99/116/005	Remicade	100 mg	Powder for concentrate for solution for infusion	Intravenous use	vial (glass)		5 vials